Status:
RECRUITING
Pressure Pain Tolerance in Relation to Balance and Strength in Children
Lead Sponsor:
Adly A Adam
Conditions:
Sickle Cell Anemia
Eligibility:
All Genders
9-14 years
Phase:
NA
Brief Summary
Sickle cell disease (SCD) is the most frequent life-threatening genetic hemoglobinopathy in the world and occurs due to the synthesis of abnormal hemoglobin S (HbS).Cells with sickle cell hemoglobin a...
Detailed Description
Sickle cell anemia is a serious life-limiting and potentially life-threatening condition that causes disruption in the lifestyle of the affected child. Pain is a common and severe symptom of sickle ce...
Eligibility Criteria
Inclusion
- Age range range was 9-14 years old.
- Could follow given instructions.
- Children with Sickle cell anemia were medically stable, and take their medications regularly.
- Children with Sickle cell anemia had experience of chronic pain that lasts more than 6 months.
- All children with Sickle cell anemia have average weight, height, and body mass index based on their age percentiles.
- All normal healthy children did not participating in regular sport activities, particularly including lower limb strengthening.
Exclusion
- Defined cardiovascular or respiratory disorders.
- Renal failure.
- Myocardial infarction, mainly within last month.
- Unstable angina.
- Recent thoracoabdominal surgery.
- Thoracic or abdominal aneurysm or current pneumothorax.
- Painful vaso-occlusive crises.
- Muscular contractures, Joints' stiffness, or deformities.
- Neuromuscular problems i.e., myositis or peripheral neuropathy.
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06529874
Start Date
February 1 2024
End Date
August 30 2025
Last Update
April 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
El-Tahrir st.- in front of Ben El-Sarayat, Ad Doqi Al Giza, Giza Governate
Giza, Egypt, 002